Agilent delivers a fully integrated workflow designed to support every stage of cancer research and immunotherapy development—from functional metabolic analysis of immune cells using Seahorse XF technology to high-throughput genomic profiling with SureSelect NGS and AVIDA-based methylation assays, complemented by advanced cellular characterization using NovoCyte flow cytometry and high-content imaging with Cytation microscopy systems. Our portfolio combines advanced instrumentation, robust reagents, and intuitive informatics to streamline decision-making, enhance experimental reproducibility, and accelerate translational progress. Driven by a history of innovation and proven expertise in life sciences, Agilent is uniquely positioned to help scientists and clinicians turn complex biological questions into actionable insights—ultimately advancing the path toward precision oncology.